These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36469363)

  • 21. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
    Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
    BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
    Peters AA; Buchanan G; Ricciardelli C; Bianco-Miotto T; Centenera MM; Harris JM; Jindal S; Segara D; Jia L; Moore NL; Henshall SM; Birrell SN; Coetzee GA; Sutherland RL; Butler LM; Tilley WD
    Cancer Res; 2009 Aug; 69(15):6131-40. PubMed ID: 19638585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
    Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
    J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor signaling pathways as a target for breast cancer treatment.
    Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
    Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth.
    Aakula A; Leivonen SK; Hintsanen P; Aittokallio T; Ceder Y; Børresen-Dale AL; Perälä M; Östling P; Kallioniemi O
    Mol Oncol; 2015 Aug; 9(7):1287-300. PubMed ID: 25907805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer.
    Cao L; Xiang G; Liu F; Xu C; Liu J; Meng Q; Lyu S; Wang S; Niu Y
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):609-620. PubMed ID: 31297554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
    Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
    Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
    Michmerhuizen AR; Lerner LM; Ward C; Pesch AM; Zhang A; Schwartz R; Wilder-Romans K; Eisner JR; Rae JM; Pierce LJ; Speers CW
    Br J Cancer; 2022 Sep; 127(5):927-936. PubMed ID: 35618789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heat shock factor 1 (HSF1) cooperates with estrogen receptor α (ERα) in the regulation of estrogen action in breast cancer cells.
    Vydra N; Janus P; Kus P; Stokowy T; Mrowiec K; Toma-Jonik A; Krzywon A; Cortez AJ; Wojtas B; Gielniewski B; Jaksik R; Kimmel M; Widlak W
    Elife; 2021 Nov; 10():. PubMed ID: 34783649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 33. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.
    Basile D; Cinausero M; Iacono D; Pelizzari G; Bonotto M; Vitale MG; Gerratana L; Puglisi F
    Cancer Treat Rev; 2017 Dec; 61():15-22. PubMed ID: 29078133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
    Du J; Zhou N; Liu H; Jiang F; Wang Y; Hu C; Qi H; Zhong C; Wang X; Li Z
    PLoS One; 2012; 7(4):e35957. PubMed ID: 22558281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer.
    Hickey TE; Dwyer AR; Tilley WD
    Br J Cancer; 2021 Dec; 125(12):1599-1601. PubMed ID: 34294894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα.
    Chen Z; Xia X; Chen H; Huang H; An X; Sun M; Yao Q; Kim K; Zhang H; Chu M; Chen R; Bhutia YD; Ganapathy V; Kou L
    Invest New Drugs; 2022 Dec; 40(6):1216-1230. PubMed ID: 36070108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
    Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
    Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of androgen receptor splice variants in clinical breast cancers.
    Hickey TE; Irvine CM; Dvinge H; Tarulli GA; Hanson AR; Ryan NK; Pickering MA; Birrell SN; Hu DG; Mackenzie PI; Russell R; Caldas C; Raj GV; Dehm SM; Plymate SR; Bradley RK; Tilley WD; Selth LA
    Oncotarget; 2015 Dec; 6(42):44728-44. PubMed ID: 26554309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profiling estrogen, progesterone, and androgen receptors in colorectal cancer in relation to gender, menopausal status, clinical stage, and tumour sidedness.
    Refaat B; Aslam A; Idris S; Almalki AH; Alkhaldi MY; Asiri HA; Almaimani RA; Mujalli A; Minshawi F; Alamri SA; AlHussain MI; Baltow BA; Alqasmi MH; Basfar GT; Alosaimi OM; Muhayya IA
    Front Endocrinol (Lausanne); 2023; 14():1187259. PubMed ID: 37206439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-1-conferred gene expression pattern in ERα
    Nawas AF; Kanchwala M; Thomas-Jardin SE; Dahl H; Daescu K; Bautista M; Anunobi V; Wong A; Meade R; Mistry R; Ghatwai N; Bayerl F; Xing C; Delk NA
    BMC Cancer; 2020 Jan; 20(1):46. PubMed ID: 31959131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.